Brivanib: A Review of Development

Future Oncol. 2012 Sep;8(9):1083-90. doi: 10.2217/fon.12.104.

Abstract

The development of new agents in oncology has focused on disrupting key pathways in oncogenesis. Both malignant angiogenesis and peptide growth factor signaling have been studied extensively and have been validated for cancer treatment. While antibody-directed therapeutics offer increased specificity, small-molecule tyrosine kinase inhibitors often have the ability to hit multiple targets. Brivanib alaninate (BMS582664) is an oral, potent selective inhibitor of both the FGF and VEGF family of receptors. It is a first-in-class FGF/VEGF inhibitor now in late-phase clinical trials. Besides its antiangiogenic activity from blocking VEGF receptor 1-3, its ability to disrupt FGF receptors 1-3 has been suggested to add additional antiangiogenic activity, overcome resistance from VEGF blockade, and block FGF-dependent tumor proliferation. In this review, we will discuss the preclinical science driving brivanib's development and the clinical data generated to date.

Publication types

  • Review

MeSH terms

  • Alanine / analogs & derivatives*
  • Alanine / pharmacokinetics
  • Alanine / pharmacology
  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Clinical Trials as Topic
  • Drug Screening Assays, Antitumor
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / mortality
  • Treatment Outcome
  • Triazines / pharmacokinetics
  • Triazines / pharmacology*

Substances

  • Angiogenesis Inhibitors
  • Triazines
  • brivanib
  • Alanine